{"id":"bedaquiline-b","safety":{"commonSideEffects":[{"rate":null,"effect":"QT prolongation"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Photosensitivity"}]},"_chembl":null,"_dailymed":{"setId":"1534c9ae-4948-4cf4-9f66-222a99db6d0e","title":"SIRTURO (BEDAQUILINE FUMARATE) TABLET [JANSSEN PRODUCTS, LP]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bedaquiline is a diarylquinoline that binds to the ATP synthase enzyme of tuberculosis bacteria, blocking ATP synthesis and causing rapid bactericidal activity. This mechanism is distinct from other TB drugs and is effective against both drug-susceptible and multidrug-resistant tuberculosis strains.","oneSentence":"Bedaquiline inhibits bacterial ATP synthase, disrupting energy production in Mycobacterium tuberculosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:58.087Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multidrug-resistant tuberculosis (MDR-TB)"},{"name":"Extensively drug-resistant tuberculosis (XDR-TB)"}]},"trialDetails":[{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT07170800","phase":"PHASE2","title":"A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets","status":"RECRUITING","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2025-09-19","conditions":"Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis","enrollment":60},{"nctId":"NCT04630145","phase":"PHASE2, PHASE3","title":"A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-01-08","conditions":"Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)","enrollment":129},{"nctId":"NCT06905522","phase":"PHASE3","title":"A PAN-USR TB Multi-Center Trial","status":"RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-06-18","conditions":"Pulmonary Tuberculosis","enrollment":610},{"nctId":"NCT07228702","phase":"PHASE1","title":"Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Vancouver Coastal Health","startDate":"2025-11","conditions":"Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection","enrollment":1},{"nctId":"NCT07227779","phase":"PHASE2","title":"B-PaLMZ for TB Meningitis","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-02-15","conditions":"Tuberculous Meningitis","enrollment":240},{"nctId":"NCT06114628","phase":"PHASE2","title":"Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-01-09","conditions":"Pulmonary Tuberculosis","enrollment":2500},{"nctId":"NCT07198685","phase":"NA","title":"6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-30","conditions":"Treat to Target, Treatment Duration","enrollment":52},{"nctId":"NCT05766267","phase":"PHASE2, PHASE3","title":"Short-course Regimens for the Treatment of Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2023-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis Infection","enrollment":288},{"nctId":"NCT02333799","phase":"PHASE3","title":"A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2015-03","conditions":"Pulmonary Tuberculosis","enrollment":109},{"nctId":"NCT06649721","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort","status":"ACTIVE_NOT_RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-11-27","conditions":"Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis","enrollment":120},{"nctId":"NCT07129629","phase":"PHASE2","title":"Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-08-20","conditions":"Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis","enrollment":45},{"nctId":"NCT04310930","phase":"PHASE2, PHASE3","title":"Finding the Optimal Regimen for Mycobacterium Abscessus Treatment","status":"RECRUITING","sponsor":"The University of Queensland","startDate":"2020-03-02","conditions":"Pulmonary Disease Due to Mycobacteria (Diagnosis)","enrollment":300},{"nctId":"NCT05007821","phase":"PHASE2","title":"Linezolid Dosing Strategies in Drug-Resistant TB","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-08-11","conditions":"Tuberculosis, Multidrug-Resistant, Tuberculosis, Tuberculosis, Pulmonary","enrollment":138},{"nctId":"NCT07076225","phase":"PHASE3","title":"Ultra-Short Regimen for Elderly DS-TB","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-07-25","conditions":"Pulmonary Tuberculosis","enrollment":300},{"nctId":"NCT03828201","phase":"PHASE2","title":"Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB","status":"RECRUITING","sponsor":"Boston University","startDate":"2022-06-07","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":220},{"nctId":"NCT05081401","phase":"PHASE3","title":"Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2022-05-23","conditions":"Multidrug Resistant Tuberculosis, Rifampicin Resistant Tuberculosis, Pre-XDR-TB","enrollment":1050},{"nctId":"NCT05971602","phase":"PHASE2","title":"Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis","status":"TERMINATED","sponsor":"Gates Medical Research Institute","startDate":"2023-07-26","conditions":"Pulmonary Tuberculosis","enrollment":93},{"nctId":"NCT04087759","phase":"PHASE1","title":"A Study of Bedaquiline 100 Milligram (mg) Tablets Administered as Different Test Formulations Compared to the Commercial Tablet Formulation (F001) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-16","conditions":"Healthy","enrollment":36},{"nctId":"NCT04179500","phase":"PHASE2","title":"A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2021-09-16","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":26},{"nctId":"NCT05278988","phase":"PHASE4","title":"A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB","status":"COMPLETED","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2021-04-01","conditions":"MDR-TB","enrollment":60},{"nctId":"NCT03338621","phase":"PHASE2, PHASE3","title":"Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2018-07-30","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":455},{"nctId":"NCT02409290","phase":"PHASE3","title":"The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB","status":"COMPLETED","sponsor":"IUATLD, Inc","startDate":"2016-03","conditions":"MDR-TB","enrollment":588},{"nctId":"NCT04608955","phase":"PHASE2","title":"Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081","status":"COMPLETED","sponsor":"Shanghai Jiatan Pharmatech Co., Ltd","startDate":"2020-10-16","conditions":"Pulmonary Tuberculosis","enrollment":99},{"nctId":"NCT03474198","phase":"PHASE2, PHASE3","title":"Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis","status":"COMPLETED","sponsor":"University College, London","startDate":"2018-03-21","conditions":"Tuberculosis, Pulmonary","enrollment":675},{"nctId":"NCT03086486","phase":"PHASE3","title":"Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2017-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":181},{"nctId":"NCT04545788","phase":"NA","title":"Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2020-08-01","conditions":"Tuberculosis","enrollment":200},{"nctId":"NCT01600963","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis","status":"WITHDRAWN","sponsor":"Janssen Infectious Diseases BVBA","startDate":"2014-03","conditions":"Multi-drug Resistant Tuberculosis","enrollment":""},{"nctId":"NCT01803373","phase":"PHASE1","title":"A Study to Assess the Relative Bioavailability of TMC207 Following Single-Dose Administrations of Two Pediatric Formulations in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Infectious Diseases BVBA","startDate":"2013-04","conditions":"Healthy, Biological Availability","enrollment":36},{"nctId":"NCT00946842","phase":"PHASE1","title":"A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy Participants","status":"COMPLETED","sponsor":"Tibotec BVBA","startDate":"2009-08","conditions":"Healthy","enrollment":28},{"nctId":"NCT01012284","phase":"PHASE1","title":"A Study of TMC207 in Patients With Moderately Impaired Hepatic Function","status":"COMPLETED","sponsor":"Tibotec BVBA","startDate":"2010-01","conditions":"Moderate Hepatic Impairment","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BDQ"],"phase":"marketed","status":"active","brandName":"Bedaquiline (B)","genericName":"Bedaquiline (B)","companyName":"Shenzhen Third People's Hospital","companyId":"shenzhen-third-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bedaquiline is a small molecule inhibitor of ATP synthase, classified as an INHIBITOR. It is primarily used to treat Multi-drug Resistant Tuberculosis and Pulmonary Disease Due to Mycobacteria.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}